-7.9%
PYPL vs GSK
+14.9%
-22.8%
-42.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.4% | +5.0% | -1.6% | +3.0% |
| 7D | +6.5% | +4.9% | +1.5% | +6.1% |
| 30D | +10.6% | +9.9% | +0.8% | +9.9% |
| 3M | +3.1% | +0.2% | +2.9% | +2.9% |
| 6M | +20.2% | +2.3% | +17.8% | +20.0% |
| YTD | +4.0% | +7.1% | -3.0% | +0.3% |
| 1Y | -7.9% | +13.1% | -21.0% | -14.0% |
| All | -7.9% | +14.9% | -22.8% | -14.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling